Axol Bioscience Ltd.. (7/17/18). "Press Release: Axol Bioscience Launch Human iPSC-derived Atrial Cardiomyocytes". Cambridge.

	Organisation	Axol Bioscience Ltd.
	Organisation 2	Metrion Biosciences Ltd.
	Product	Human iPSC-derived Atrial Cardiomyocytes (Axol Bioscience)
	Product 2	drug discovery services
	Person	Shi, Yichen (Axol Bioscience 201304– CEO + Co-founder)
	Person 2	Rogers, Marc (Metrion Biosciences 201510– Managing Director + CSO)

A consistent and reproducible model for drug development, toxicity testing and disease modelling applications

Axol Bioscience, the human cell culture specialist, provide highly validated primary cells and iPSC-derived cells together with optimised media and growth supplements, launch their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease.

Generated from the same donor as Axol’s highly validated Human iPSC-derived Ventricular Cardiomyocytes, this physiologically relevant human iPSC-derived cell line is quick and easy to use, ready in just 7-days from thaw, for electrophysiology, cardiac contractility study, screening and the investigation of cardiomyopathies.

"We are delighted to announce the launch of Axol's atrial cardiomyocytes. We are proud to say that they are the first and only iPSC-derived atrial cardiomyocyte product currently available to the research market," said Yichen Shi, Chief Executive Officer, Axol Bioscience. "These cells will provide researchers with a quick and easy to use platform for studying human atrial muscle cells, creating models of atrial-specific diseases, and later developing assays for identifying disease modifying treatments."

"Our staff find iPSC-derived cells much easier to work with, reliably expressing the ion channel biophysics and pharmacology expected of native human atrial cardiomyocytes," said Marc Rogers, PhD, Founding Director and Chief Scientific Officer, Metrion Biosciences. "We have worked closely with Axol Bioscience during the development and validation of their iPSC-derived atrial cardiomyocytes, confirming them as a robust and reliable stem cell reagent across multiple batches, from pilot to scale-up stage.

Validated through an industry recognised third party and validated against the Comprehensive in vitro Pro-arrhythmia Assay (CiPA) guidelines, Axol’s Human iPSC-derived Atrial Cardiomyocytes express typical targets, ion channels and currents (Kv1.5, Ikir3.x, Ikur, IKACh, MLC2a & ANP) essential for the screening of cross target effects, the development of atrial specific target drugs, and the investigation of atrial fibrillation and inherited cardiac conditions. The overall potential and application of the Human iPSC-derived Atrial Cardiomyocytes can be enriched when cultured with Axol’s serum-free Cardiomyocyte Maintenance Medium, reducing variability and enhancing consistency in their culture.

For more information on Axol’s Human iPSC-derived Atrial Cardiomyocytes, please follow the link.

About Axol Bioscience

Axol Bioscience, the human cell culture specialist, provide highly validated primary cells and iPSC-derived cells together with optimised media and growth supplements. Through the supply of differentiated cells derived from healthy donors and patients of specific disease backgrounds, Axol aims to develop the best human cell biology research tools to advance medical research and drug discovery. Combining our passion for science with quality, innovation and customer service, we deliver the robust and reliable products our customers need to advance their research faster. To find out more, visit www.axolbio.com.

Record changed: 2018-07-27